Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
China News
Nicox Reports First Sale of Zerviate in China by Partner Ocumension
France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million
Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...
Clinical Trial Updates for Ophthalmic Candidates, December 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million
Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD
HuidaGene Therapeutics announced Nov. 4 that the US FDA had cleared its investigational new drug (IND) application for a Phase I trial of HG202, a gene therapy candidate targeting wet age-related m...
October 2024 Ophthalmic News Briefs
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China
France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...
NovaSight Gains Approval in China for CureSight System for Amblyopia
Israel-based NovaSight reported Sept. 4 that its CureSight eye-tracking system for amblyopia in children had gained approval from Chinese regulators, expanding the device’s availability to the thre...
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Samsara Says First SING IMT for AMD Has Been Implanted in China
Samsara Vision, of Far Hills, New Jersey, announced July 22 that the first SING IMT procedure for age-related macular degeneration (AMD) had been completed in China. The SING IMT, which stands for ...
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME
China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...
Volume-Based Procurement Could Upend China’s IOL Market
Alcon offered big discounts in China’s public sector centralized volume-based procurement (VBP) cycle for intraocular lenses (IOLs). The company’s low bids in seven of the eight bidding categories ...
Chinese Regulators Accept NDA from Innovent for IBI311 in Thyroid Eye Disease
China’s Innovent Biologics announced May 20 that Chinese regulators had accepted the new drug application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody for thyroid e...
May 2024 Ophthalmic News Briefs
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
ArcScan Computer-Controlled Ophthalmic Ultrasound Gains Approval in China
ArcScan announced May 1 that its Insight 100 computer-controlled ophthalmic ultrasound imaging device received National Medical Products Administration (NMPA) approval in China. ArcScan, of Denver,...
2024 APAO Congress Brainstorms How to Expand Access to Eye Care; Companies Showcase Tech Boom
Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...
Regulators in Singapore Accept NDA from AffaMed for Dextenza
Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint
China’s Innovent Biologics announced Feb. 19 that the primary endpoint had been achieved in the company’s Phase II/III trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF...
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya
Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...
November 2023 Ophthalmic News Briefs
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD
China’s Skyline Therapeutics announced Oct. 19 that the National Medical Products Administration had cleared its investigational new drug application for a clinical trial of SKG0106, a one-time int...
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market
China’s AffaMed Technologies announced Oct. 10 that it had entered into an agreement with SIFI, of Italy, to manufacture, develop, and commercialize SIFI’s Evolux enhanced monofocal intraocular len...
First Patient Dosed in Phase III Trial of Innovent’s Anti-VEGF, Anti-Complement Candidate for Wet AMD
China’s Innovent Biologics announced Oct. 8 that the first patient had been dosed in a Phase III trial of efdamrofusp alfa (IBI302), a recombinant fully human anti-VEGF and anti-complement bispecif...
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate
London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...
September 2023 Ophthalmic News Briefs
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate
Neurophth Therapeutics announced Sept. 6 that the Australian Therapeutic Goods Administration had cleared its gene therapy candidate NFS-05 for clinical trials targeting autosomal dominant optic at...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.